Is Prebiotics Constipation Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Prebiotics Constipation Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Evidence has accumulated in recent years that gut microbiota dysbiosis may be an early event in PD, driving neuroinflammation and neurodegeneration through the gut-brain axis (,). [Wang Wanhong (2026); evidence level 3] - 7 8 9 10 11 12 10 Studies have shown that fecal SCFA levels are significantly reduced in PD patients, while plasma acetate levels are abnormally elevated-a paradoxical finding possibly related to intestinal barrier disruption and systemic inflammation (,). [Wang Wanhong (2026); evidence level 3] - For example, butyrate, an important SCFA, exerts neuroprotective effects by inhibiting histone deacetylases (HDACs) and activating G protein-coupled receptors (e.g., GPR41/43), but its levels are markedly reduced in PD patients (). [Wang Wanhong (2026); evidence level 3] - Its pathology involves progressive loss of dopaminergic neurons in the substantia nigra and abnormal α-synuclein aggregation, leading to typical motor symptoms such as tremor, rigidity, and bradykinesia (,). [Wang Wanhong (2026); evidence level 3] - Although microbiota-based interventions show potential therapeutic value in selected patients, current evidence is limited by substantial heterogeneity in study design, small sample sizes, inconsistent microbiome signatures, and limited long-term safety data. [Chen Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.